05.10.2021 kl 18:21 2572

Product and market developments update

En positiv, en nøytral og en dårlig nyhet.

GCAL: in final negotiations with first global partner
The commercial development of GCAL is progressing well. The company advises that it is in the final stage of negotiating a commercial collaboration contract regarding GCAL with a leading global diagnostics provider. The goal is to start the commercial roll-out during 1H 2022. In addition, Gentian has entered into promising commercial collaboration agreements with specialised distributors in several countries so far this year, most recently in South Korea.

SARS-CoV-2 Ab: on track for launch in Q4 2021
The SARS-CoV-2 Ab project is in the final development phase. The project is on track for launch towards the end of Q4 2021, and the company is encouraged by the increasing interest for antibody testing as a tool to manage immunisation status.

NT-proBNP: reference method achieved – launch date to be rescheduled.

However, to fully qualify the reference method, more tests are required, and the company has therefore initiated further trials to substantiate the method.

The optimisation of the NT-proBNP assay has proven to be more complex than assumed. Although several milestones have been achieved, it is now apparent that the technical development will have to continue further before the assay optimisation phase can be concluded.

Other pipeline projects and funding
Gentian advises that other ongoing pipeline development projects are developing according to plans.

Invitation to Q3 2021 and R&D presentation
Gentian will provide more information on its projects as new information becomes available.
Redigert 05.10.2021 kl 18:21

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.